Clinical Trial: Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Brief Summary: Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

Detailed Summary: Patients with Graves' disease were divided into two groups: groups receiving oral 1α-D3 in addition to propylthiouracil (PTU) and groups receiving placebos in addition to PTU. Comparison of DC maturation were performed before and after the oral 1α-D3. DC maturation was assessed based on the expression of DC markers (HLA-DR, CD80, CD40, CD83, CD14 and CD206) and the ratio of cytokines interleukin-12/IL-10.
Sponsor: Dr Cipto Mangunkusumo General Hospital

Current Primary Outcome: Dendritic cells maturation level [ Time Frame: up to 9 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: fT4 levels [ Time Frame: up to 9 months ]

Original Secondary Outcome: Same as current

Information By: Dr Cipto Mangunkusumo General Hospital

Dates:
Date Received: December 7, 2016
Date Started: July 2014
Date Completion:
Last Updated: December 12, 2016
Last Verified: December 2016